Erratum: Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: Results of a large dutch cohort study (The American Journal of Gastroenterology (2010) 105 (2430-2436) DOI: 10.1038/ajg.2010.334);Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: Results of a large dutch cohort study

American Journal of Gastroenterology

Volumn 105, Issue 11, 2010, Pages 2430-2436

  Van Boxel, Ofke S ^a   Van Oijen, Martijn G H ^a,b   Hagenaars, Matthijs P ^c   Smout, A J P M ^a   Siersema, Peter D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Achmea Health Insurance ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CORONARY ARTERY DISEASE; DRUG MECHANISM; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSTABLE ANGINA PECTORIS;

EID: 78149280679     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.391     Document Type: Erratum

References (31)

1. http://www.who.int/cardiovascular-diseases/en/. Accessed October 2009.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis ofrandomised trials of antiplatelet therapy for prevention of death, myocardialinfarction, and stroke in high risk patients. BMJ 2002 ; 324 : 71-86.
3. Anand SS , Yusuf S. Oral anticoagulant therapy in patients with coronaryartery disease: a meta-analysis. JAMA 1999 ; 282 : 2058-67.
4. Sabatine MS , Cannon CP , Gibson CM et al. Addition of clopidogrel toaspirin and fibrinolytic therapy for myocardial infarction with ST-segmentelevation. N Engl J Med 2005 ; 352 : 1179-89.
5. Simon T , Verstuyft C , Mary-Krause M et al. Genetic determinantsof response to clopidogrel and cardiovascular events. N Engl J Med2009 ; 360 : 363-75.
6. Van de WF , Bax J , Betriu A et al. Management of acute myocardial infarctionin patients presenting with persistent ST-segment elevation: the Task Forceon the Management of ST-Segment Elevation Acute Myocardial Infarctionof the European Society of Cardiology. Eur Heart J 2008 ; 29 : 2909-45.
7. Antman EM , Hand M , Armstrong PW et al. 2007 focused update of theACC/AHA 2004 guidelines for the management of patients with ST-elevationmyocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol 2008 ; 51 : 210-47.
8. Bhatt DL , Scheiman J , Abraham NS et al. ACCF/ACG/AHA 2008 expertconsensus document on reducing the gastrointestinal risks of antiplatelettherapy and NSAID use: a report of the American College of CardiologyFoundation Task Force on Clinical Expert Consensus Documents. Circulation2008 ; 118 : 1894-909.
9. Sibbing D , Morath T , Stegherr J et al. Impact of proton pump inhibitors onthe antiplatelet Effects of clopidogrel. Th romb Haemost 2009 ; 101 : 714-9.
10. Gilard M , Arnaud B , Le GG et al. influence of omeprazol on the antiplateletaction of clopidogrel associated to aspirin. J Th romb Haemost2006 ; 4 : 2508-9.
11. Pezalla E , Day D , Pulliadath I. Initial assessment of clinical impact of a druginteraction between clopidogrel and proton pump inhibitors. J Am CollCardiol 2008 ; 52 : 1038-9.
12. Ishizaki T , Horai Y. Review article: cytochrome P450 and the metabolismof proton pump inhibitors\-emphasis on rabeprazole. Aliment PharmacolTher 1999 ; 13 (Suppl 3) : 27-36.
13. Gilard M , Arnaud B , Cornily JC et al. influence of omeprazole on theantiplatelet action of clopidogrel associated with aspirin: the randomized,double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am CollCardiol 2008 ; 51 : 256-60.
14. Ho PM , Maddox TM , Wang L et al. Risk of adverse outcomes associatedwith concomitant use of clopidogrel and proton pump inhibitors followingacute coronary syndrome. JAMA 2009 ; 301 : 937-44.
15. Juurlink DN , Gomes T , Ko DT et al. A population-based study of thedrug interaction between proton pump inhibitors and clopidogrel. CMAJ2009 ; 180 : 713-8.
16. O' Donoghue ML , Braunwald E , Antman EM et al. Pharmacodynamic Effectand clinical efficacy of clopidogrel and prasugrel with or without a protonpumpinhibitor: an analysis of two randomised trials. Lancet 2009 ; 374 : 989-97.
17. Bhatt DL , Cryer B , Contant CF et al. COGENT: a Prospective, Randomized,Placebo-Controlled Trial of omeprazole in patients receivingaspirin and clopidogrel. Transvascular Cardiovascular Therapeutics AnnualMeeting, September 2009 (abstract).
18. Kwok CS , Loke YK. Meta-analysis: the Effects of proton pump inhibitorson cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010 ; 31 : 810-23.
19. http://www.fda.gov/Drugs/DrugSafety. Accessed October 2009.
20. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf. Accessed October 2009.
21. http://www.whocc.no/atcddd/. Accessed Ocotber 2009.
22. http://www.who.int/classifications/icd/en/. Accessed October 2009.
23. az-Rubio M , Moreno-Elola-Olaso C , Rey E et al. Symptoms of gastrooesophagealreflux: prevalence, severity, duration and associated factors ina Spanish population. Aliment Pharmacol Ther 2004 ; 19 : 95-105.
24. Mohammed I , Nightingale P , Trudgill NJ. Risk factors for gastro-oesophagealreflux disease symptoms: a community study. Aliment Pharmacol Ther2005 ; 21 : 821-7.
25. Hampel H , Abraham NS , El-Serag HB. Meta-analysis: obesity and the riskfor gastroesophageal reflux disease and its complications. Ann Intern Med2005 ; 143 : 199-211.
26. Chan FK , Ching JY , Hung LC et al. Clopidogrel versus aspirin andesomeprazole to prevent recurrent ulcer bleeding. N Engl J Med2005 ; 352 : 238-44.
27. Lanas A , Garcia-Rodriguez LA , Arroyo MT et al. Effect of antisecretorydrugs and nitrates on the risk of ulcer bleeding associated with nonsteroidalanti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am JGastroenterol 2007 ; 102 : 507-15.
28. Petri H , Urquhart J. Channeling bias in the interpretation of drug Effects. Stat Med 1991 ; 10 : 577-81.
29. A randomised, blinded, trial of clopidogrel versus aspirin in patients atrisk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet1996 ; 348 : 1329-39.
30. Bhatt DL , Fox KA , Hacke W et al. Clopidogrel and aspirin versus aspirinalone for the prevention of atherothrombotic events. N Engl J Med2006 ; 354 : 1706-17.
31. Keller TT , Squizzato A , Middeldorp S. Clopidogrel plus aspirin versusaspirin alone for preventing cardiovascular disease. Cochrane Database SystRev 2007 ; CD005158.